Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 1/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 19/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 0.67 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6378090 | 0.92 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL6373356 | 0.91 | LTB4R (0.98) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL8583520 | 0.89 | LTB4R (0.83) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| Sc-41390 SCHEMBL6372088 | 0.84 | LTB4R (0.84) | LTB4RLTB4R2 | |
| SCHEMBL6370354 | 0.80 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL8650764 | 0.80 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL8950060 | 0.79 | LTB4R (0.78) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL7625803 | 0.79 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL10838232 | 0.79 | LTB4R (0.88) | LTB4RLTB4R2CYSLTR2CYSLTR1 | |
| SCHEMBL9372183 | 0.78 | LTB4R (1.00) | LTB4RLTB4R2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933272-B1 | Use of non-peptidyl compounds for the treatment of insulin related ailments | HELMERHORST ERIK (AU) | 2005-08-23 | — | — | US | disclosed |
| EP-1115422-A4 | USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS | UNIV CURTIN TECH (AU) | 2003-01-29 | — | — | EP | disclosed |
| EP-1115422-A1 | USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000016798-A1 | USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2000-03-30 | — | — | WO | disclosed |
| US-5552441-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS AND RESPIRATORY SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5324743-A | Leukotriene B4 antagonists | ELI LILLY AND COMPANY (US) | 1994-06-28 | — | — | US | disclosed |